PhaseBio Pharmaceuticals Accounts Payable Turnover

Accounts Payable Turnover of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Accounts Payable Turnover growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Accounts Payable Turnover for 2020 was 0.0 (a NaN% decrease from previous year)
  • Annual Accounts Payable Turnover for 2019 was 0.0 (a -100.0% decrease from previous year)
  • Annual Accounts Payable Turnover for 2018 was 0.09 (a -57.8% decrease from previous year)
  • Twelve month Accounts Payable Turnover ending September 29, 2021 was 0.0 (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Accounts Payable Turnover decreased by -100.0% year-over-year
Trailing Accounts Payable Turnover for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
0.0 0.0 0.24 0.15
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Accounts Payable Turnover of PhaseBio Pharmaceuticals

Most recent Accounts Payable Turnoverof PHAS including historical data for past 10 years.

Interactive Chart of Accounts Payable Turnover of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Accounts Payable Turnover for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0
2019 0.0
2018 0.09
2017 0.22
2016 0.0

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.